FELDENE Drug Patent Profile
✉ Email this page to a colleague
When do Feldene patents expire, and when can generic versions of Feldene launch?
Feldene is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in FELDENE is piroxicam. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the piroxicam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Feldene
A generic version of FELDENE was approved as piroxicam by TEVA on December 11th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FELDENE?
- What are the global sales for FELDENE?
- What is Average Wholesale Price for FELDENE?
Summary for FELDENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 160 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for FELDENE |
| What excipients (inactive ingredients) are in FELDENE? | FELDENE excipients list |
| DailyMed Link: | FELDENE at DailyMed |
Recent Clinical Trials for FELDENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | Early Phase 1 |
| Pamukkale University | Phase 4 |
Pharmacology for FELDENE
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for FELDENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-002 | Apr 6, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-003 | Apr 6, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FELDENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-002 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-002 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-003 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-002 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-003 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | FELDENE | piroxicam | CAPSULE;ORAL | 018147-002 | Apr 6, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FELDENE
See the table below for patents covering FELDENE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 7706338 | ⤷ Sign Up | |
| United Kingdom | 1414887 | ⤷ Sign Up | |
| U.S.S.R. | 833159 | METHOD OF PREPARING 1,1-DIOXIDE OF N-(2-PYRIDYL OR THIAZOLYL)-3,4-DIHYDRO-2-METHYL-4-OXO-2H-1,2-BENZOTHIZIN-3-CARBOXAMIDE | ⤷ Sign Up |
| Malaysia | 8100269 | 3,4-DIHYDRO-2-METHYL-4-OXO-2H-1,2-BENZOTHIAZINE-3-CARBOXYLIC ACID -1,1DIOXIDE AND A PROCESS FOR ITS PREPARATION | ⤷ Sign Up |
| Bulgaria | 41307 | METHOD FOR PREPARING 3, 4- DIHYDRO- 2- METHYL- 4- OXO- 2H- 1, 2- BENZOTHIAZINE- 3- CARBONIC ACID- 1, 1 - DIOXIDE AND ITS 2- PYRIDYL AND 2- THIAZOLYL DERIVATIVES | ⤷ Sign Up |
| Cyprus | 1127 | PROCESS FOR THE PREPARATION OF N-(2-PYRIDYL)-AND N-(2-THIAZOYL)-3,4-DIHYDRO-1-METHYL-4-OXO-2H-1,2-BENZOTHIAZINE-3-CARBOXYLIC ACID-1,1-DIOXIDE USED IN SAME | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
